• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case

    6/24/24 3:47:37 PM ET
    $AZN
    $GEHC
    $JNJ
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Electronics
    Health Care
    Get the next $AZN alert in real time by email

    The U.S. Supreme Court has supported 21 pharmaceutical and medical equipment companies, led by AstraZeneca Plc (NYSE:AZN), in a lawsuit accusing them of funding terrorism that harmed American troops and civilians in Iraq.

    The justices dismissed a lower court’s ruling that had allowed the case to proceed, directing the court to reconsider the lawsuit.

    The plaintiffs allege that major U.S. and European pharmaceutical and device manufacturers, including Pfizer Inc (NYSE:PFE), GE Healthcare USA, a unit of GE Healthcare Technologies Inc (NASDAQ:GEHC), Johnson & Johnson (NYSE:JNJ), and F. Hoffmann-La Roche (OTC:RHHBY), provided corrupt payments to the Hezbollah-sponsored militia group Jaysh al-Mahdi.

    These payments were allegedly made to secure medical supply contracts from Iraq’s health ministry, which the plaintiffs claim was controlled by the militia group.

    Initiated in 2017 in federal court in Washington, Reuters notes that the lawsuit seeks unspecified damages under the Anti-Terrorism Act, allowing Americans to pursue claims related to acts of international terrorism.

    In 2020, a federal trial judge dismissed the lawsuit, but the U.S. Court of Appeals for the District of Columbia Circuit revived the case in 2022, the report added.

    Reuters noted that in a joint statement on Monday, pharmaceutical and device companies expressed approval of the Supreme Court’s ruling and called for the lawsuit’s dismissal based on a previous Supreme Court decision involving Twitter, now known as X.

    The companies argued that the ruling, which protected Twitter from liability under the Anti-Terrorism Act, should also apply to their case.

    The Supreme Court’s decision in the Twitter case established that aiding and abetting claims under the Anti-Terrorism Act requires proof that a defendant “consciously and culpably” participated in a terror act to aid its success.

    The plaintiffs in the current case argued that the pharmaceutical and device companies’ knowing bribes to terrorists were more culpable than Twitter’s alleged failure to exclude a terrorist group from its platform.

    The case now returns to the lower court for reconsideration, as per the Supreme Court’s instructions.

    Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

    Image via Pixabay

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $GEHC
    $JNJ
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    GE HealthCare Technologies Inc.
    $GEHC
    1/15/2026$77.00Neutral → Sell
    UBS
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Pfizer Inc.
    $PFE
    12/2/2025$26.00Neutral
    Citigroup
    More analyst ratings

    $AZN
    $GEHC
    $JNJ
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00

    2/12/26 7:23:25 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GEHC
    $JNJ
    $PFE
    SEC Filings

    View All

    SEC Form 10-K filed by Pfizer Inc.

    10-K - PFIZER INC (0000078003) (Filer)

    2/26/26 12:44:01 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/26/26 8:59:56 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/25/26 10:40:05 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GEHC
    $JNJ
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

    Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancerRARITAN, N.J., Feb. 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The re

    2/26/26 2:30:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

    VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegravir VH499 demonstrates good tolerability, supporting twice-yearly dosing intervals ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV.1 Results show a single-dose injection could maintain drug levels for up

    2/25/26 2:00:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

    94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir These phase IIb results reinforce lotivibart's ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined w

    2/25/26 2:00:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GEHC
    $JNJ
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Lankler Douglas M exercised 122,907 shares at a strike of $33.82 and covered exercise/tax liability with 119,009 shares, increasing direct ownership by 2% to 163,177 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/27/26 6:35:09 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Vice President Sahni Payal exercised 56,888 shares at a strike of $33.82 and covered exercise/tax liability with 55,149 shares, increasing direct ownership by 7% to 27,667 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/27/26 6:35:10 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP & Controller Damico Jennifer B. exercised 17,558 shares at a strike of $33.82 and covered exercise/tax liability with 17,048 shares, increasing direct ownership by 4% to 12,696 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/27/26 6:35:07 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GEHC
    $JNJ
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GEHC
    $JNJ
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GEHC
    $JNJ
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $AZN
    $GEHC
    $JNJ
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GEHC
    $JNJ
    $PFE
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    GE HealthCare announces cash dividend for first quarter of 2026

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patie

    2/12/26 6:11:00 PM ET
    $GEHC
    Medical Electronics
    Health Care